Holly McConville

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung et al. · Nature Medicine · 2022 · 500 citations · Full text

Medicine, Oncology, Pharmacology +14

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall et al. · Nature Medicine · 2025 · 71 citations

Life Sciences, Immunology, Translational Sciences +14

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

David Porter, J. Joseph Melenhorst, Wei‐Ting Hwang et al. · Blood · 2014 · 64 citations

Life Sciences, Immunology, Oncology +14

Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

David L. Porter, Jan J. Melenhorst, Wei‐Ting Hwang et al. · Journal of Clinical Oncology · 2016 · 33 citations

Medicine, Immunology, Oncology +17

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

David L. Porter, Michael Kalos, Stephan A. Grupp et al. · Blood · 2013 · 29 citations

Life Sciences, Immunology, Oncology +13